1i73
From Proteopedia
(New page: 200px<br /> <applet load="1i73" size="450" color="white" frame="true" align="right" spinBox="true" caption="1i73, resolution 1.40Å" /> '''COMPLEX OF PRO-LEU-...) |
|||
| Line 1: | Line 1: | ||
| - | [[Image:1i73. | + | [[Image:1i73.jpg|left|200px]]<br /><applet load="1i73" size="350" color="white" frame="true" align="right" spinBox="true" |
| - | <applet load="1i73" size=" | + | |
caption="1i73, resolution 1.40Å" /> | caption="1i73, resolution 1.40Å" /> | ||
'''COMPLEX OF PRO-LEU-L-TRP PHOSPHONATE WITH THE CATALITIC DOMAIN OF MATRIX METALLO PROTEINASE-8 (MET80 FORM)'''<br /> | '''COMPLEX OF PRO-LEU-L-TRP PHOSPHONATE WITH THE CATALITIC DOMAIN OF MATRIX METALLO PROTEINASE-8 (MET80 FORM)'''<br /> | ||
| Line 8: | Line 7: | ||
==About this Structure== | ==About this Structure== | ||
| - | 1I73 is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with CA and ZN as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Neutrophil_collagenase Neutrophil collagenase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.24.34 3.4.24.34] Full crystallographic information is available from [http:// | + | 1I73 is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=CA:'>CA</scene> and <scene name='pdbligand=ZN:'>ZN</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Neutrophil_collagenase Neutrophil collagenase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.24.34 3.4.24.34] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1I73 OCA]. |
==Reference== | ==Reference== | ||
| Line 29: | Line 28: | ||
[[Category: hydrolase]] | [[Category: hydrolase]] | ||
| - | ''Page seeded by [http:// | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Fri Feb 15 15:59:39 2008'' |
Revision as of 13:59, 15 February 2008
|
COMPLEX OF PRO-LEU-L-TRP PHOSPHONATE WITH THE CATALITIC DOMAIN OF MATRIX METALLO PROTEINASE-8 (MET80 FORM)
Overview
Two crystal structures of human neutrophil collagenase (HNC, MMP-8), one, complexed with a primed- and the other with an unprimed-side inhibitor, were determined using synchrotron radiation at 100 K. Both inhibitors, contain non-hydroxamate zinc-binding functions. The, Pro-Leu-L-Trp(P)(OH)(2) occupies the unprimed region of the active site, furnishes new structural information regarding interaction between the, catalytic zinc ion and the phosphonate group, and is the only example of, occupation of the S(1) subsite of MMP-8 by the bulky tryptophan side, chain. The (R)-2-(biphenyl-4-ylsulfonyl)-1,2,3, 4-tetrahydroisochinolin-3-carboxylic acid, a conformationally constrained, D-Tic derivative, accommodates its biphenyl substituent into the deep, primary specificity S(1)' subsite, inducing a widening of the entrance to, this pocket; this modification of the protein, mainly consisting in a, shift of the segment centered at Pro217, is observed for the first time in, MMP-8 complexes. Cation-aromatic interactions can stabilize the formation, of both complexes, and the beneficial effect of aromatic substituents in, proximity of the catalytic zinc ion is discussed. The phosphonate group, bound to either a primed- or unprimed-side inhibitor maintains the same, relative position with respect to the catalytic zinc ion, suggesting that, this binding function can be exploited for the design of combined, inhibitors assembled to interact with both primed and unprimed regions of, the active cleft.
About this Structure
1I73 is a Single protein structure of sequence from Homo sapiens with and as ligands. Active as Neutrophil collagenase, with EC number 3.4.24.34 Full crystallographic information is available from OCA.
Reference
Two crystal structures of human neutrophil collagenase, one complexed with a primed- and the other with an unprimed-side inhibitor: implications for drug design., Gavuzzo E, Pochetti G, Mazza F, Gallina C, Gorini B, D'Alessio S, Pieper M, Tschesche H, Tucker PA, J Med Chem. 2000 Sep 7;43(18):3377-85. PMID:10978185
Page seeded by OCA on Fri Feb 15 15:59:39 2008
